Post-treatment hypermutation in a recurrent diffuse glioma with H3.3 p.G34 Mutation.

Matthew D WoodTanaya NeffJoshua P NickersonChristina SayamaAhmed M RaslanPrakash AmbadyChristopher L CorlessKellie J Nazemi

Published in: Neuropathology and applied neurobiology (2020)

Diffuse gliomas with H3F3A point mutations affecting histone H3.3 glycine position 34 are a distinct glioma subtype mostly occurring in the cerebral hemispheres of paediatric and young adult patients. These tumours have a high rate of MGMT promoter hypermethylation, a predictive biomarker for response to the DNA alkylating agent temozolomide (TMZ). Post-treatment TMZ-associated hypermutation is a mechanism for TMZ resistance in recurrent isocitrate dehydrogenase (IDH) wildtype glioblastoma and may be seen in association with tumour progression in lower-grade IDH-mutant diffuse astrocytic gliomas.

Keyphrases

low grade
high grade
wild type
emergency department
dna methylation
intensive care unit
gene expression
single molecule